Lipid-Lowering Agents - Poland

Poland

The Lipid-Lowering Agents market in Poland is expected to witness a substantial increase in revenue, with projections indicating that it will reach €22.82m by 2024.
Furthermore, an annual growth rate of -0.39% is anticipated from 2024 to 2029, resulting in a market volume of €22.38m by the end of the forecast period.
When compared globally, United States is expected to generate the highest revenue, amounting to €4,094.00m in 2024.
In Poland, the market for lipid-lowering agents is witnessing a surge in demand due to increasing awareness about cardiovascular health.

Key regions: Europe, Brazil, France, Australia, Germany

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The demand for Lipid-Lowering Agents in Poland has been steadily increasing in recent years.

Customer preferences: Patients in Poland are becoming increasingly health-conscious and are seeking preventative measures to avoid chronic diseases such as cardiovascular disease. As a result, there has been a growing demand for Lipid-Lowering Agents to manage cholesterol levels.

Trends in the market: The market for Lipid-Lowering Agents in Poland is expected to continue to grow as the population ages and the prevalence of cardiovascular disease increases. Additionally, the market is expected to see increased competition as more generic versions of popular drugs become available.

Local special circumstances: The Polish government has implemented various policies to reduce the burden of cardiovascular disease on the healthcare system. For example, the National Health Fund provides reimbursement for Lipid-Lowering Agents for patients with high cholesterol levels. This has helped to increase access to these drugs for patients who may not have been able to afford them otherwise.

Underlying macroeconomic factors: Poland's economy has been growing steadily in recent years, which has led to an increase in disposable income for many citizens. This has allowed more patients to afford Lipid-Lowering Agents, which has contributed to the growth of the market. Additionally, the government's focus on preventative healthcare has helped to increase awareness of the importance of managing cholesterol levels, which has also contributed to the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.